Publication | Closed Access

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineHematologyImmunologyImmune Checkpoint InhibitorPharmacotherapyFrontline TreatmentAdult T-cell Leukemia-lymphomaImmunotherapyOncologyCancer Research